| Followers | 236 |
| Posts | 10817 |
| Boards Moderated | 0 |
| Alias Born | 07/17/2006 |
Wednesday, October 23, 2013 7:46:43 AM
Good Lord...
Never in my life have I ever heard such pessimism about a great stock..
Buffett says the stock market is like a partner in business, every day he comes to work..The problem is he is a manic-depressive..So when he's manic he wont sell his part of the company for any amount..but when he is depress, he will sell out cheap...So when should you be approaching him about buying him out?
Wake up...Some facts
The sNDA has not been declined..IMO, (a minority view) the FDA will decide not to go down that path, regardless of who's behind this..For the FDA this is dice rolling big time and please do not think these guys have any special immunity in federal court. This is not about the FDA deciding on an sNDA..This is about the FDA violating a contract..In this case the FDA is going to have to prove their case, and their case reeks to high heavens.
The company has an FDA approved product even with the modest start they should be at the $100 mil revenue mark by this time next year.
The company is not in financial peril, it has in the neighborhood of $210 million in cash..Debt payments are $40 mil till the end of 2014. And it is making good money.
Dumping drug reps is not going to effect sales in any meaningful way..They need to go in a different direction marketing the drug..
Right now they are giving the shares away..I'm keeping mine, and buying more..
":>) JL
Never in my life have I ever heard such pessimism about a great stock..
Buffett says the stock market is like a partner in business, every day he comes to work..The problem is he is a manic-depressive..So when he's manic he wont sell his part of the company for any amount..but when he is depress, he will sell out cheap...So when should you be approaching him about buying him out?
Wake up...Some facts
The sNDA has not been declined..IMO, (a minority view) the FDA will decide not to go down that path, regardless of who's behind this..For the FDA this is dice rolling big time and please do not think these guys have any special immunity in federal court. This is not about the FDA deciding on an sNDA..This is about the FDA violating a contract..In this case the FDA is going to have to prove their case, and their case reeks to high heavens.
The company has an FDA approved product even with the modest start they should be at the $100 mil revenue mark by this time next year.
The company is not in financial peril, it has in the neighborhood of $210 million in cash..Debt payments are $40 mil till the end of 2014. And it is making good money.
Dumping drug reps is not going to effect sales in any meaningful way..They need to go in a different direction marketing the drug..
Right now they are giving the shares away..I'm keeping mine, and buying more..
":>) JL
Recent AMRN News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:04 AM
- Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization • GlobeNewswire Inc. • 01/09/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2026 12:05:27 PM
- Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities • GlobeNewswire Inc. • 01/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:10 PM
- New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients • GlobeNewswire Inc. • 11/09/2025 09:15:00 PM
- Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025 • GlobeNewswire Inc. • 11/03/2025 01:30:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2025 08:30:06 PM
